Genpharmasec Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company submitted the mandatory certificate under Regulation 74(5) of SEBI regulations on April 8, 2026. The filing was signed by Mr. Sohan Chaturvedi, Whole Time Director and CFO (DIN: 09629728), and submitted to BSE Limited's Compliance Department.

Certificate Confirmation

The certificate was issued by Satellite Corporate Services Pvt. Ltd, the company's Registrar and Share Transfer Agent (RTA). According to the RTA's confirmation dated April 6, 2026, no physical share certificates were received for dematerialization during the quarter ended March 31, 2026.

The RTA, which holds Registration No. INR000003639 as a Category-I Registrar to an Issue & Share Transfer Agent, confirmed compliance with standard verification procedures. The certificate states that in cases where physical certificates are received, they undergo due verification, mutilation, and cancellation, with the depository's name being substituted as the registered owner.

Regulatory Framework

Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 requires companies to submit quarterly certificates regarding physical share certificates received for dematerialization. This regulation ensures transparency in the dematerialization process and maintains accurate records of securities transactions.

The filing demonstrates Genpharmasec Limited's commitment to regulatory compliance and transparent reporting practices. The company maintains its registered office at 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Soc Ltd., Akurli Road, Kandivali (East), Mumbai 400101.

Genpharmasec Limited conducted its separate meeting of independent directors on March 24, 2026, fulfilling its regulatory obligations under the Companies Act, 2013 and SEBI listing regulations. The meeting represents a key governance milestone for the pharmaceutical company as it ensures compliance with mandatory corporate governance requirements.

Meeting Details and Compliance Framework

The independent directors' meeting was held in accordance with Schedule IV of the Companies Act, 2013 and Regulation 25(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The session was conducted on Tuesday, March 24, 2026, demonstrating the company's commitment to maintaining robust governance standards.

Key Agenda Items and Performance Review

The independent directors addressed three critical governance areas during their deliberations. The meeting focused on comprehensive performance assessments across multiple organizational levels, ensuring thorough evaluation of the company's leadership structure.

The directors undertook the following key activities:

• Board Performance Review: Evaluated the performance of non-independent directors and assessed the board's overall effectiveness
• Chairperson Assessment: Reviewed the chairperson's performance while incorporating feedback from both executive and non-executive directors
• Information Flow Analysis: Assessed the quality, quantity, and timeliness of information exchange between management and the board of directors

Governance and Information Management

The meeting emphasized the critical importance of effective information flow within the organization. The independent directors specifically evaluated whether the management provides adequate, timely, and quality information to enable the board to perform its duties effectively and reasonably.

This assessment ensures that board members have access to necessary information for informed decision-making and strategic oversight. The evaluation process strengthens the overall governance framework by identifying potential gaps in communication channels between management and the board.

Regulatory Filing and Documentation

Genpharmasec Limited promptly communicated the meeting outcome to BSE Limited through an official filing. The documentation was signed by Mr. Siddhesh Shende, Independent Director with DIN: 09629926, ensuring proper authentication and compliance with exchange requirements.

The company's proactive approach to regulatory communication demonstrates its commitment to transparency and adherence to listing obligations. This separate meeting of independent directors represents an essential component of the company's annual governance cycle, reinforcing stakeholder confidence in its corporate governance practices.